View details of this raise on Seedstage

Lumberton, MS

Developing innovative therapies for oncology and dental health to improve patient care.

• Innovative Cancer Therapy: Triamdocaine is designed to alleviate severe oral mucositis, enhancing quality of life for cancer patients.
• Dental Health Solutions: Acyclonine MUM provides targeted relief for various oral conditions, improving dental care outcomes.
• Secured Patents: Patents valid through 2039 ensure market exclusivity and a competitive edge.
• Clinical Trials: Phase 2 clinical trials are underway to validate the efficacy of Triamdocaine.
• Strategic Market Positioning: RAM Pharmaceuticals is positioned in high-growth markets with a focus on oncology and dental health.

RAM Pharmaceuticals is advancing its mission to improve patient care through innovative therapies targeting oncology and dental health. The company is developing Triamdocaine, a dry powder spray therapy designed to alleviate severe oral mucositis (SOM), a common side effect of cancer treatments. This therapy combines anesthetic, antiviral, and anti-inflammatory agents to provide targeted relief, enhancing the quality of life for patients undergoing radiation and chemotherapy. With FDA IND approval secured, RAM Pharmaceuticals is conducting Phase 2 clinical trials to further validate the efficacy of Triamdocaine.

In addition to oncology, RAM Pharmaceuticals is addressing dental health needs with Acyclonine MUM, a therapy for managing oral conditions such as mucosal ulcerations and post-operative pain. The company’s dual-focus business model includes RAMtherapeutics for oncology product development and RAMdental for dental care solutions. By securing patents through 2039, RAM Pharmaceuticals ensures a competitive edge and market exclusivity. The company is strategically positioned in high-growth markets, aiming to expand its reach through partnerships and scalable manufacturing processes. RAM Pharmaceuticals is committed to transforming patient care by addressing unmet needs in both oncology and dental sectors.

Company Info

RAM Pharmaceuticals develops therapies for oncology and dental care, focusing on improving patient quality of life.

RAM Pharmaceuticals is a clinical-stage company focused on developing innovative therapies for oncology and dental care. Their flagship product, Triamdocaine, is designed to alleviate severe oral mucositis (SOM), a common side effect of cancer treatments, by providing targeted relief through a unique combination of anesthetic, antiviral, and anti-inflammatory agents. This product aims to improve the quality of life for cancer patients by addressing pain and discomfort associated with SOM.

In addition to oncology, RAM Pharmaceuticals extends its commitment to dental health with Acyclonine MUM, a therapy that offers targeted relief for various oral conditions, including mucosal ulcerations and post-operative pain. By focusing on patient-centered outcomes and securing patents through 2039, RAM Pharmaceuticals positions itself as a leader in supportive care, addressing unmet needs in both oncology and dental sectors.